
    
      PROTOCOL OUTLINE: This is a randomized study. Patients are randomly assigned to recombinant
      human growth hormone (GH) and oxandrolone versus GH and placebo.

      GH is administered by daily subcutaneous injection and oxandrolone is given every day by
      mouth. Treatment continues for 3 years; estrogen is offered after year 2.

      A study duration of 8 years is anticipated.
    
  